semaglutide phase 2 A clinical trial has demonstrated that bimagrumab, when combined with semaglutide, resulted in significant weight loss for trial participants while maintaining lean muscle mass – suggesting a promising approach for Reorder Page - AquaVita

Among members who were taking a GLP-1 at the time they were surveyed, less than a third indicated that they expected to be on the medication for the foreseeable future." Compare that to almost half of members who selected until I reach a target weight or other outcome. Similarly, when we asked our members what they found appealing about the idea of trying a GLP-1, they used terms like kickstart, jumpstart, and boost, all of which we believe suggests our members may view medication as short-term support on a long-term journey

Results Patient disposition Data of 30,84,719 patients diagnosed with T2DM were available in the EMR (January 2022January 2024)

Most animal models of NASH lack sufficient validation regarding disease progression

The pattern of fat loss varies between individuals based on genetics, hormones, age, and baseline fat distribution

While these findings should be interpreted with appropriate cautionthe study included only individuals with obesity (BMI 30 kg/m), and larger, more diverse trials are neededthey raise an important question